Additional file 3 of Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice

Supplementary Material 3: Supplementary Fig. 3. In vivo characterization of immunocytokines sensitivity in syngeneic orthotopic mouse PDAC models. a) Plot showing tumor growth curves of KPC06 tumor-bearing mice randomly assigned to receive once a week for 2 weeks: vehicle, as CTR, L19-IL2 (100 µg/mouse), L19mIL12 (12 µg/mouse), mIL2-F8-mTNF(mut) (40 µg/mouse), L19mTNF (4 µg/mouse), standard chemotherapy with gemcitabine 10 mg/kg + abraxane 3 mg/kg (Gem/Abx). Means ± SD were reported b) Kaplan–Meier curves showing survival of KPC06 mice divided according to each experimental condition. c) Variation of body weight in the different treatment groups.